|
乳腺癌是全世界女性最常见的恶性肿瘤。2005年，中国新诊断乳腺癌大约27.2万例，死于乳腺癌超过7万例。每年大约3%～10%的新诊断乳腺癌患者诊断时已经远处转移。大约30%～40%的诊断时早期乳腺癌可发展为晚期乳腺癌。晚期乳腺癌患者的5年生存比例仅约20%，中位总生存2～3年。虽然晚期乳腺癌仍然难以治愈，但是医师通过开发新药和优化治疗方式，可以缓解临床症状、改善生活质量、进一步延长生存。晚期乳腺癌患者选择治疗方案时也有自己的意愿。而且，对于多线治疗后的难治型乳腺癌治疗尚无标准推荐意见。为了向临床医师提供参考，中国专家组对无法手术的局部晚期乳腺癌、复发或转移性乳腺癌的诊断、治疗和预后进行了分析、总结和讨论，已于2016年制订中国晚期乳腺癌临床诊断治疗专家共识，并于2018年更新。 2020年7月25日，美国癌症学会《癌症》中国乳腺癌特刊在线发表中国医学科学院肿瘤医院徐兵河、李青、马飞、王淑莲、王翔、袁芃、张频、复旦大学附属肿瘤医院胡夕春、王碧芸、王中华、吴炅、江苏省肿瘤医院冯继峰、殷咏梅、河北医科大学第四医院耿翠芝、中国医科大学附属第一医院金锋、滕月娥、重庆医科大学附属第一医院厉红元、大连医科大学附属第二医院李曼、广东省人民医院廖宁、中山大学附属肿瘤医院刘冬耕、王树森、福建省肿瘤医院刘健、中山大学孙逸仙纪念医院刘强、上海交通大学医学院附属仁济医院陆劲松、河南省肿瘤医院刘真真、闫敏、湖南省肿瘤医院欧阳取长、安徽省立医院潘跃银、上海交通大学医学院附属瑞金医院沈坤炜、辽宁省肿瘤医院孙涛、天津医科大学肿瘤医院佟仲生、张瑾、青岛大学附属医院王海波、解放军总医院第五医学中心王涛、浙江省肿瘤医院王晓稼、山东省肿瘤医院王永胜、解放军总医院杨俊兰、哈尔滨医科大学附属肿瘤医院张清媛、四川大学华西医院郑鸿等学者联合起草的中国晚期乳腺癌临床诊断治疗专家共识（2018年）英文版，全文共16页。 相关链接 Cancer. 2020 Aug 15;126 Suppl 16:3867-3882. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Xu B, Hu X, Feng J, Geng C, Jin F, Li H, Li M, Li Q, Liao N, Liu D, Liu J, Liu Q, Lu J, Liu Z, Ma F, Ouyang Q, Pan Y, Shen K, Sun T, Teng Y, Tong Z, Wang B, Wang H, Wang S, Wang S, Wang T, Wang X, Wang X, Wang Y, Wang Z, Wu J, Yan M, Yang J, Yin Y, Yuan P, Zhang J, Zhang P, Zhang Q, Zheng H. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Fudan University Shanghai Cancer Center, Shanghai, China; Jiangsu Cancer Hospital, Nanjing, China; The Fourth Hospital, Hebei Medical University, Shijiazhuang, China; The First Affiliated Hospital, China Medical University, Shenyang, China; The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; The Second Affiliated Hospital, Dalian Medical University, Dalian, China; Guangdong General Hospital, Guangzhou, China; Cancer Center, Sun Yat-sen University, Guangzhou, China; Fujian Cancer Hospital, Fuzhou, China; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Renji Hospital, Shanghai Jiaotong University, Shanghai, China; Henan Cancer Hospital, Zhengzhou, China; Hunan Cancer Hospital, Changsha, China; Anhui Provincial Hospital, Hefei, China; Ruijin Hospital of Shanghai Jiaotong University, Shanghai, China; Liaoning Cancer Hospital, Shenyang, China; Cancer Hospital, Tianjin Medical University, Tianjin, China; Affiliated Hospital of Medical College, Qingdao University, Qingdao, China; The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, China; Zhejiang Cancer Hospital, Hangzhou, China; Shandong Cancer Hospital, Jinan, China; People's Liberation Army General Hospital, Beijing, China; Cancer Hospital, Harbin Medical University, Harbin, China; West China Hospital, Sichuan University, Chengdu, China. Breast cancer is the most common malignant tumor among women in the world. In 2005, there were approximately 272,000 new cases diagnosed and more than 70,000 deaths from breast cancer in China. Of the patients who are newly diagnosed with breast cancer each year, approximately 3% to 10% have distant metastases at the time of diagnosis. Of those who have early stage disease at diagnosis, from 30% to 40% will develop advanced breast cancer. The 5-year survival rate for patients with advanced breast cancer is only 20%, and the median overall survival (OS) is 2 to 3 years. Although advanced breast cancer is still difficult to cure, physicians can relieve clinical symptoms, improve quality of life, and further prolong survival through the development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own preferences in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after multiline therapy. To offer a reference for clinicians, a Chinese expert group has analyzed, summarized, and discussed related research data on the diagnosis, treatment, and prognosis of inoperable, locally advanced breast cancer and recurrent or metastatic breast cancer and has developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018). KEYWORDS: advanced breast neoplasms; diagnosis; expert consensus; treatment PMID: 32710660 DOI: 10.1002/cncr.32832 |
|
|
